By Sheeba M. | June 06, 2026
Federal Policy Signals Could Reshape Cannabis Stock Valuations
Cannabis industry valuations remain compressed relative to traditional retail and consumer goods companies, primarily due to Schedule I status under federal law. Recent policy signals from Congress suggest momentum toward federal reform—a shift that could dramatically reprice the entire sector.
The Curaleaf and Trulieve valuations currently trade at 3-5x revenue multiples compared to 6-8x for comparable retail companies. If federal policy changes, this valuation arbitrage could compress quickly as institutional capital enters the market.
Key Policy Catalysts
Three major policy developments could trigger sector revaluation:
- SAFE Banking Act: Would allow cannabis operators to access traditional banking services and capital markets more easily.
- Schedule III Reclassification: Would lower regulatory burden and enable federal-level corporate banking relationships.
- State-Level Legalization: New market openings in states like Florida, New York, and California continue to drive revenue growth.
Institutional Money is Waiting
Asset managers have signaled willingness to deploy significant capital into cannabis once federal barriers fall. Current institutional holdings in Greenthumb Industries and Curaleaf suggest large players are already positioning for policy change.
Smart money is watching this closely: a 20-30% valuation rerating could be forthcoming if any of these catalysts materialize.
Sources
- Congress.gov — SAFE Banking Act status
- White House Briefing — Federal cannabis policy updates
- Marijuana Policy Project — Policy tracking and analysis
Track cannabis stocks with the Weedstock Real-Time Tracker